Skip to main content
Top
Gepubliceerd in: Quality of Life Research 8/2021

02-04-2021

Factors predicting missing instruments in three cancer randomized clinical trials

Auteurs: Michael J. Palmer, Harriet Richardson, Dongsheng Tu, Michael Brundage

Gepubliceerd in: Quality of Life Research | Uitgave 8/2021

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Missing patient-reported outcome (PRO) data can seriously threaten the validity of randomized clinical trials (RCTs). Identifying which factors predict missing instruments may help researchers develop strategies to prevent it from happening. This study examined the association of factors with time to the first missing instrument after randomization in three cooperative group RCTs.

Methods

We performed descriptive analyses and Cox proportional hazards regressions for three RCTs selected from the Canadian Cancer Trials Group: MA17 (breast cancer), PR7 (prostate cancer), and LY12 (non-Hodgkin’s lymphoma). The outcome was the time from randomization to the first missing instrument. Variables for 15 factors were used as covariates based on availability and previously-reported putative associations with missing PRO data.

Results

Nine percent of 1352 subjects on MA17, 37% of 923 subjects on PR7, and 59% of 477 subjects on LY12 had a missing instrument. Twenty-five percent of subjects on MA17 had first missing instrument within 4.6 years. The median time to first missing instrument was: not observed for MA17, 7.3 years for PR7, 0.12 years for LY12. Cox regression revealed statistically significant independent associations with outcome for only five factors: baseline age (PR7) and level of well-being (LY12), and centre level of activity (LY12), presence of post-graduate residency training program (MA17, PR7), and centre geographic location (PR7, LY12).

Conclusion

Many factors reported to have association with missing instruments do not seem to predict time to the first missing instrument after randomization in RCTs. Context is important in understanding the few that may.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Priestman, T. J., & Baum, M. (1976). Evaluation of quality of life in patients receiving treatment for advanced breast cancer. The Lancet, 1, 899–901.CrossRef Priestman, T. J., & Baum, M. (1976). Evaluation of quality of life in patients receiving treatment for advanced breast cancer. The Lancet, 1, 899–901.CrossRef
3.
go back to reference Stockler, M. R., et al. (2014). Patient-reported outcome results from the open-label phase III Aurelia trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. Journal of Clinical Oncology, 32, 1309–1316.CrossRef Stockler, M. R., et al. (2014). Patient-reported outcome results from the open-label phase III Aurelia trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. Journal of Clinical Oncology, 32, 1309–1316.CrossRef
4.
go back to reference Szklo, M., & Nieto, F. J. (2007). Epidemiology beyond the basics (2nd ed.). Jones and Bartlett Publishers. Szklo, M., & Nieto, F. J. (2007). Epidemiology beyond the basics (2nd ed.). Jones and Bartlett Publishers.
5.
go back to reference Moinpour, C. M., et al. (2000). Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. Psycho-Oncology, 9, 340–354.CrossRef Moinpour, C. M., et al. (2000). Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. Psycho-Oncology, 9, 340–354.CrossRef
6.
go back to reference Lipscomb, J., Reeve, B. B., Clauser, S. B., et al. (2007). Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. Journal of Clinical Oncology, 25, 5133–5140.CrossRef Lipscomb, J., Reeve, B. B., Clauser, S. B., et al. (2007). Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. Journal of Clinical Oncology, 25, 5133–5140.CrossRef
7.
go back to reference National Research Council. (2010). The prevention and treatment of missing data in clinical trials. Panel on handling missing data in clinical trials. Committee on national statistics, division of behavioral and social sciences and education. The National Academies Press. National Research Council. (2010). The prevention and treatment of missing data in clinical trials. Panel on handling missing data in clinical trials. Committee on national statistics, division of behavioral and social sciences and education. The National Academies Press.
8.
go back to reference Little, R. L., D’Agostino, R., Cohen, M. L., et al. (2012). The prevention and treatment of missing data in clinical trials. New England Journal of Medicine, 367, 1355–1361.CrossRef Little, R. L., D’Agostino, R., Cohen, M. L., et al. (2012). The prevention and treatment of missing data in clinical trials. New England Journal of Medicine, 367, 1355–1361.CrossRef
9.
go back to reference Little, R. J., Cohen, M. L., Dickersin, K., et al. (2012). The design and conduct of clinical trials to limit missing data. Statistics in Medicine, 31, 3433–3443.CrossRef Little, R. J., Cohen, M. L., Dickersin, K., et al. (2012). The design and conduct of clinical trials to limit missing data. Statistics in Medicine, 31, 3433–3443.CrossRef
10.
go back to reference Calvert, M., Kyte, D., Mercieca-Bebber, R., et al. (2018). Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: The SPIRIT-PRO extension. JAMA, 319, 483–494.CrossRef Calvert, M., Kyte, D., Mercieca-Bebber, R., et al. (2018). Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: The SPIRIT-PRO extension. JAMA, 319, 483–494.CrossRef
12.
go back to reference Calvert, M., et al. (2013). Reporting of patient-reported outcomes in randomized trials: The CONSORT PRO extension. JAMA, 309, 814–822.CrossRef Calvert, M., et al. (2013). Reporting of patient-reported outcomes in randomized trials: The CONSORT PRO extension. JAMA, 309, 814–822.CrossRef
13.
go back to reference Palmer, M. J., Mercieca-Bebber, R., King, M., Calvert, M., Richardson, H., & Brundage, M. (2018). A systematic review and development of a classification framework for factors associated with missing patient-reported outcome data. Clinical Trials, 15, 95–106.CrossRef Palmer, M. J., Mercieca-Bebber, R., King, M., Calvert, M., Richardson, H., & Brundage, M. (2018). A systematic review and development of a classification framework for factors associated with missing patient-reported outcome data. Clinical Trials, 15, 95–106.CrossRef
14.
go back to reference Land, S. R., Ritter, M. W., Costantino, J. P., et al. (2007). Compliance with patient-reported outcomes in multicenter clinical trials: Methodologic and practical approaches. Journal of Clinical Oncology, 25, 5113–5120.CrossRef Land, S. R., Ritter, M. W., Costantino, J. P., et al. (2007). Compliance with patient-reported outcomes in multicenter clinical trials: Methodologic and practical approaches. Journal of Clinical Oncology, 25, 5113–5120.CrossRef
15.
go back to reference Osoba, D., & Zee, B. (1998). Completion rates in health-related quality-of-life assessment: Approach of the National Cancer Institute of Canada Clinical Trials Group. Statistics in Medicine, 17, 603–612.CrossRef Osoba, D., & Zee, B. (1998). Completion rates in health-related quality-of-life assessment: Approach of the National Cancer Institute of Canada Clinical Trials Group. Statistics in Medicine, 17, 603–612.CrossRef
16.
go back to reference Hahn, H. A., Webster, K. A., Cella, D., & Fairclough, D. L. (1998). Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: problems and solutions. Statistics in Medicine, 17, 547–559.CrossRef Hahn, H. A., Webster, K. A., Cella, D., & Fairclough, D. L. (1998). Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: problems and solutions. Statistics in Medicine, 17, 547–559.CrossRef
17.
go back to reference Palmer, M. J., Mercieca-Bebber, R., King, M., Calvert, M., Richardson, H., & Brundage, M. (2017). What evidence suggests a relationship between patient age and missing PRO data on randomized clinical trials (RCTs)? Quality of Life Research, 26(Supplement 1), 138–139. Palmer, M. J., Mercieca-Bebber, R., King, M., Calvert, M., Richardson, H., & Brundage, M. (2017). What evidence suggests a relationship between patient age and missing PRO data on randomized clinical trials (RCTs)? Quality of Life Research, 26(Supplement 1), 138–139.
18.
go back to reference Stang, A. (2003). Nonresponse research: An underdeveloped field in epidemiology. European Journal of Epidemiology, 18, 929–931.CrossRef Stang, A. (2003). Nonresponse research: An underdeveloped field in epidemiology. European Journal of Epidemiology, 18, 929–931.CrossRef
19.
go back to reference Osoba, D., Bezjak, A., Brundage, M., & Pater, J. (2007). Evaluating health-related quality of life in cancer clinical trials: The National Cancer Institute of Canada Clinical Trials Group experience. Value Health, 10(Suppl 2), S138–S145.CrossRef Osoba, D., Bezjak, A., Brundage, M., & Pater, J. (2007). Evaluating health-related quality of life in cancer clinical trials: The National Cancer Institute of Canada Clinical Trials Group experience. Value Health, 10(Suppl 2), S138–S145.CrossRef
20.
go back to reference Fletcher, J. (2007). What is heterogeneity and is it important? BMJ, 334, 94–96.CrossRef Fletcher, J. (2007). What is heterogeneity and is it important? BMJ, 334, 94–96.CrossRef
21.
go back to reference Whelan, T. J., et al. (2005). Assessment of quality of life in MA.17, a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. Journal of Clinical Oncology, 23, 6931–6940.CrossRef Whelan, T. J., et al. (2005). Assessment of quality of life in MA.17, a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. Journal of Clinical Oncology, 23, 6931–6940.CrossRef
22.
go back to reference Crook, J. M., et al. (2012). Intermittent androgen suppression for rising PSA level after radiotherapy. New England Journal of Medicine, 367, 895–903.CrossRef Crook, J. M., et al. (2012). Intermittent androgen suppression for rising PSA level after radiotherapy. New England Journal of Medicine, 367, 895–903.CrossRef
23.
go back to reference Crump, M., et al. (2014). Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC CTG LY.12. Journal of Clinical Oncology, 32, 3490–3496.CrossRef Crump, M., et al. (2014). Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC CTG LY.12. Journal of Clinical Oncology, 32, 3490–3496.CrossRef
24.
go back to reference McDowell, I. (2006). Measuring health: A guide to rating scales and questionnaires. Oxford University Press.CrossRef McDowell, I. (2006). Measuring health: A guide to rating scales and questionnaires. Oxford University Press.CrossRef
25.
go back to reference Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001). The EORTC QLQ-C30 scoring manual (3rd ed.). European Organisation for Research and Treatment of Cancer. Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001). The EORTC QLQ-C30 scoring manual (3rd ed.). European Organisation for Research and Treatment of Cancer.
26.
go back to reference Webster, K., Cella, D., & Yost, K. (2003). The functional assessment of chronic illness therapy (FACIT) measurement system: Properties, applications, and interpretation. Health and Quality of Life Outcomes, 1, 79.CrossRef Webster, K., Cella, D., & Yost, K. (2003). The functional assessment of chronic illness therapy (FACIT) measurement system: Properties, applications, and interpretation. Health and Quality of Life Outcomes, 1, 79.CrossRef
27.
go back to reference Vittinghoff, E., Glidden, D. V., Shiboski, S. C., & McCulloch, C. E. (2012). Regression methods in statistics. Linear, logistic, survival, and repeated measures models (2nd ed.). Springer. Vittinghoff, E., Glidden, D. V., Shiboski, S. C., & McCulloch, C. E. (2012). Regression methods in statistics. Linear, logistic, survival, and repeated measures models (2nd ed.). Springer.
28.
go back to reference Kleinbaum, D. G., Kupper, L. L., Muller, K. E., & Nizam, A. (1997). Applied regression analysis and other multivariable methods (3rd ed.). Duxbury Press. Kleinbaum, D. G., Kupper, L. L., Muller, K. E., & Nizam, A. (1997). Applied regression analysis and other multivariable methods (3rd ed.). Duxbury Press.
29.
go back to reference Greenland, S., & Rothman, K. J. (2008). Introduction to stratified analyses. In K. J. Rothman, S. Greenland, & T. L. Lash (Eds.), Modern epidemiology (3rd ed.). Lippincott Williams & Wilkins. Greenland, S., & Rothman, K. J. (2008). Introduction to stratified analyses. In K. J. Rothman, S. Greenland, & T. L. Lash (Eds.), Modern epidemiology (3rd ed.). Lippincott Williams & Wilkins.
30.
go back to reference Spruance, S. L., Reid, J. E., Grace, M., & Samore, M. (2004). Hazard ratio in clinical trials. Antimicrobial Agents and Chemotherapy, 48, 2787–2792.CrossRef Spruance, S. L., Reid, J. E., Grace, M., & Samore, M. (2004). Hazard ratio in clinical trials. Antimicrobial Agents and Chemotherapy, 48, 2787–2792.CrossRef
31.
go back to reference Reisine, S., Fifield, J., & Winkelman, D. K. (2000). Characteristics of rheumatoid arthritis patients: Who participates in long-term research and who drops out? Arthritis Care and Research, 13, 3–10.CrossRef Reisine, S., Fifield, J., & Winkelman, D. K. (2000). Characteristics of rheumatoid arthritis patients: Who participates in long-term research and who drops out? Arthritis Care and Research, 13, 3–10.CrossRef
32.
go back to reference Hopwood, P., Harvey, A., Davies, J., et al. (1997). Survey of the administration of quality of life questionnaires in three multicentre randomised trials in cancer. European Journal of Cancer, 34, 49–57.CrossRef Hopwood, P., Harvey, A., Davies, J., et al. (1997). Survey of the administration of quality of life questionnaires in three multicentre randomised trials in cancer. European Journal of Cancer, 34, 49–57.CrossRef
33.
go back to reference Courvoisier, D. S., Eid, M., & Lischetzke, T. (2012). Compliance to a cell phone-based ecological momentary assessment study: The effect of time and personality characteristics. Psychological Assessment, 24, 713–720.CrossRef Courvoisier, D. S., Eid, M., & Lischetzke, T. (2012). Compliance to a cell phone-based ecological momentary assessment study: The effect of time and personality characteristics. Psychological Assessment, 24, 713–720.CrossRef
34.
go back to reference Sadura, A., Pater, J., Osoba, D., Levine, M., Palmer, M., & Bennet, K. (1992). Quality-of-life assessment: Patient compliance with questionnaire completion. Journal of the National Cancer Institute, 84, 1023–1026.CrossRef Sadura, A., Pater, J., Osoba, D., Levine, M., Palmer, M., & Bennet, K. (1992). Quality-of-life assessment: Patient compliance with questionnaire completion. Journal of the National Cancer Institute, 84, 1023–1026.CrossRef
35.
go back to reference Bernhard, J., Cella, D., Coates, A. S., et al. (1998). Missing quality of life data in cancer clinical trials: Serious problems and challenges. Statistics in Medicine, 17, 517–532.CrossRef Bernhard, J., Cella, D., Coates, A. S., et al. (1998). Missing quality of life data in cancer clinical trials: Serious problems and challenges. Statistics in Medicine, 17, 517–532.CrossRef
36.
go back to reference Ganz, P. A., Haskell, C. M., Figlin, R. A., et al. (1988). Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and Functional Living Index: Cancer. Cancer, 61, 849–856.CrossRef Ganz, P. A., Haskell, C. M., Figlin, R. A., et al. (1988). Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and Functional Living Index: Cancer. Cancer, 61, 849–856.CrossRef
37.
go back to reference Concato, J., Peduzzi, P., Holford, T. R., & Feinstein, A. R. (1995). Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. Journal of Clinical Epidemiology, 48, 1495–1501.CrossRef Concato, J., Peduzzi, P., Holford, T. R., & Feinstein, A. R. (1995). Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. Journal of Clinical Epidemiology, 48, 1495–1501.CrossRef
38.
go back to reference Peduzzi, P., Concato, J., Feinstein, A. R., & Holford, T. R. (1995). Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. Journal of Clinical Epidemiology, 48, 1503–1510.CrossRef Peduzzi, P., Concato, J., Feinstein, A. R., & Holford, T. R. (1995). Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. Journal of Clinical Epidemiology, 48, 1503–1510.CrossRef
39.
go back to reference Mercieca-Bebber, R., Palmer, M. J., Brundage, M., et al. (2016). Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: A systematic review. British Medical Journal Open, 6, e010938. Mercieca-Bebber, R., Palmer, M. J., Brundage, M., et al. (2016). Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: A systematic review. British Medical Journal Open, 6, e010938.
40.
go back to reference Wright, J. R., Crooks, D., Ellis, P. M., Mings, D., & Whelan, T. J. (2002). Factors that influence the recruitment of patients to phase III studies in Oncology. Cancer, 95, 1584–1591.CrossRef Wright, J. R., Crooks, D., Ellis, P. M., Mings, D., & Whelan, T. J. (2002). Factors that influence the recruitment of patients to phase III studies in Oncology. Cancer, 95, 1584–1591.CrossRef
41.
go back to reference Price, K. C., Barrett, B. K., & Roark, J. M. (2006). Cancer and Leukemia Group B clinical research associates committee. Clinical Cancer Research, 12(11 Suppl), 3642–3644.CrossRef Price, K. C., Barrett, B. K., & Roark, J. M. (2006). Cancer and Leukemia Group B clinical research associates committee. Clinical Cancer Research, 12(11 Suppl), 3642–3644.CrossRef
Metagegevens
Titel
Factors predicting missing instruments in three cancer randomized clinical trials
Auteurs
Michael J. Palmer
Harriet Richardson
Dongsheng Tu
Michael Brundage
Publicatiedatum
02-04-2021
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 8/2021
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-021-02818-0

Andere artikelen Uitgave 8/2021

Quality of Life Research 8/2021 Naar de uitgave